ALK and neoplasm: In contrast, high overall numbers of de novo SNVs and mutations in the druggable genes, ALK, BRAF and FGFR1, were only detected in a subset of relapse samples from patient CB1002 compared to the primary tumour at diagnosis (in line with previous studies reporting an increase in mutational burden and de novo MAPK pathway mutations in relapsed neuroblastoma26,29).